Search clinical trials for: HS-10241 Almonertinib

Total 255 results

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
Hansoh BioMedical R&D Company

Not yet recruiting

A Phase Ib/III Clinical Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer
Atridia Pty Ltd.

Completed

A Phase I Trial of HS-10241 in Solid Tumors

Solid Tumors | Neoplasm

Australia
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

Carcinoma | Solid Tumor, Adult

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
First People's Hospital of Hangzhou

Not yet recruiting

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Brain Metastases | EGFR Positive Non-small Cell Lung Cancer

China
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
Shanghai Chest Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)

Lung Cancer | EGFR Gene Mutation
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors (HS:Hansoh;)

Advanced Cancer

China
Shanghai Chest Hospital

Not yet recruiting

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (ATTACK)

NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease

Recruiting

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Poor Performance Status | Malignant Tumor of Lung

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial (AUTUMN)

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. (APPROACH)

Lung Cancer

China
Shanghai Cancer Hospital, China

Recruiting

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
Yuan Chen

Recruiting

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

NSCLC, Stage III

China
Sun Yat-sen University

Enrolling by invitation

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Safety of Almonertinib

China
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Metastatic Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Brain Metastases | Radiotherapy | EGFR Activating Mutation

China
Zhejiang Cancer Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases (ACHIEVE)

Lung Cancer

China
BioLineRx, Ltd.

Terminated

A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021

Healthy | Volunteers

Israel
Sun Yat-sen University

Recruiting

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance (APPEAR)

Safety

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383

Cough

China
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Non Small Cell Lung Cancer | EGFR Activating Mutation | Stage III NSCLC

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10353 in Chinese Participants.

Major Depressive Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

Treatment Resistant Depressive Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383

Cough

China
Qingdao Sino-Cell Biomedicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; West China... and other collaborators

Recruiting

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Cough
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction

Healthy

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1a Study in Healthy Participants

Healthy
Heartseed Inc.

Recruiting

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) (LAPiS)

Heart Failure | Ischemic Heart Disease

Japan
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia (HS-25-III-01)

Primary Hypercholesterolemia
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
Hansoh BioMedical R&D Company

Not yet recruiting

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Vasomotor Symptoms

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of HS-10511 in Healthy Subjects

Hypertrophic Cardiomyopathy
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10518 in Healthy Female Participants

Endometriosis
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10517 in Chinese Adult Participants

COVID-19

China

3

Subscribe